Cancer Archives

News and Trends 14 Dec 2022

ImaginAb launches trial to study neoadjuvant immunotherapy

ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety of neoadjuvant immune checkpoint inhibitor treatment of stage III surgically resectable melanoma through use of CD8 ImmunoPET. ImaginAb is a global biotechnology company focused on […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Etcembly reveals breakthrough in optimizing TCR assets

Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid tumors. The company’s machine learning platform EMLy (Etcembly machine learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine-learning-based optimization with empirical validation has facilitated the rapid […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Asieris doses first patient in bladder cancer diagnostic trial

Asieris Pharmaceuticals has announced that Hexvix, a drug used for bladder cancer diagnosis, completed dosing for the first patient in its real-world clinical study at Hainan General Hospital Lecheng Branch. Hexvix has been approved in the U.S. and many European countries. The combined use of Hexvix and blue light cystoscopy (BLC) for the management of […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

cancer protein degradation sibylla biotech

Interview 14 Dec 2022

Sibylla Biotech: how physicists met biologists to discover new drugs

Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain how their interdisciplinary approach can speed up drug discovery in the protein degradation space. Protein degradation is a hot field in the biotech industry, with many pharmaceutical companies forging lucrative deals with protein degradation players. […]

December 14, 2022 - 9 minutesmins - By Jonathan Smith

News and Trends 14 Dec 2022

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023

Ofer Sharon is the CEO of OncoHost, a biotech company in the precision oncology space. A physician by training, Sharon has leveraged his experience in pharma drug development and entrepreneurship to lead OncoHost through the development of PROphet, the company’s host response profiling platform, which will launch in the U.S. for non-small cell lung cancer […]

December 14, 2022 - 7 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Therabest and Glycotope to assess breast cancer combination treatment

Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK (natural killer) cell therapies from various cell sources have demonstrated exciting results in early clinical trials […]

December 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

brain cancer glioblastoma divide and conquer

News and Trends 12 Dec 2022

Enterome completes patient enrollment for recurrent glioblastoma study

Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […]

December 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Step Pharma announces promising pre-clinical cancer data

Step Pharma has announced encouraging pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, STP938. The data were presented at the 64th American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic […]

December 12, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […]

December 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […]

December 9, 2022

News and Trends 8 Dec 2022

PDCline Pharma presents first immunological results from trial with PDClung01

PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […]

December 8, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

ImaginAb launches trial to study neoadjuvant immunotherapy

Etcembly reveals breakthrough in optimizing TCR assets

Asieris doses first patient in bladder cancer diagnostic trial

Sibylla Biotech: how physicists met biologists to discover new drugs

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023

Therabest and Glycotope to assess breast cancer combination treatment

OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data

Enterome completes patient enrollment for recurrent glioblastoma study

Step Pharma announces promising pre-clinical cancer data

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

PDCline Pharma presents first immunological results from trial with PDClung01

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!